All In Biotech

Drug Trial Radar · NCT02360579

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma

Last checked: Nov 20, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

220

Actual

Start

Sep 24, 2015

Primary completion

Oct 24, 2024

Study completion Oct 24, 2024

Sponsor

Lead sponsor
Iovance Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 10, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA LD) preconditioning regimen.

Conditions

  • Metastatic Melanoma

Interventions

  • LifileucelBiological

    A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with lifileucel followed by IL-2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Assessment for Objective Response RateTime frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months

Locations

57 sites in 8 countries. Site status is shown where the registry gives one.

  • University of California San Diego Moores Cancer Center

    La Jolla, California

  • The Angeles Clinic and Research Institute

    Los Angeles, California

  • University of California Los Angeles - David Geffen School of Medicine - Westwood Rheumatology

    Los Angeles, California

  • California Pacific Medical Center

    San Francisco, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • University of Miami

    Miami, Florida

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • University of Florida Health Cancer Center

    Orlando, Florida

  • University of South Florida H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Indiana University

    Indianapolis, Indiana

  • James Graham Brown Cancer Center

    Louisville, Kentucky

  • University of Minnesota, Masonic Cancer Center

    Minneapolis, Minnesota

  • Atlantic Health System

    Morristown, New Jersey

  • Rutgers University

    New Brunswick, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • New York University Langone Medical Center

    New York, New York

  • Providence Cancer Center Oncology and Hematology Care Clinic

    Portland, Oregon

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center - Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Virginia Commonwealth University

    Richmond, Virginia

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Centre Léon Bérard

    Lyon, Auvergne-Rhône-Alpes, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, Auvergne-Rhône-Alpes, France

  • Gustave Roussy Cancer Campus

    Villejuif, Île-de-France Region, France

  • Hôpital Dupuytren

    Limoges, Limousin, France

  • Universitätsklinikum Würzburg

    Würzburg, Germany

  • Universitaetsklinikum Heidelberg

    Heidelberg, Baden-Wurttemberg, Germany

  • Universitaetsklinikum Tuebingen (UKT) - Suedwestdeutschen Tumorzentrum - Zentrum für Neuroonkologie

    Tübingen, Baden-Wurttemberg, Germany

  • Universitätsklinikum Erlangen

    Erlangen, Bavaria, Germany

  • Klinikum Rechts der Isar der Technischen Universität München

    München, Bavaria, Germany

  • Universitätsklinikum Carl Gustav Carus

    Dresden, Saxony, Germany

  • Universitätsklinikum Leipzig

    Leipzig, Saxony, Germany

  • Universitätsklinikum Halle

    Halle, Saxony-Anhalt, Germany

  • Universitätsklinikum Schleswig-Holstein - Campus Lübeck

    Lübeck, Schleswig-Holstein, Germany

  • Szegedi Tudomanyegyetem Szent-Györgyi Albert Klinikai Központ

    Szeged, Csongrád megye, Hungary

  • Istituto Europeo di Oncologia

    Milan, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale

    Naples, Italy

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

    Meldola, Forli-cesena, Italy

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.